US NIH National Cancer Institute: Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

This opportunity uses the U01 Research Project – Cooperative Agreements funding mechanism.

The National Cancer Institute invites applications for its utilising the prostate, lung, colorectal and ovarian cancer (PLCO) biospecimens resource to bridge gaps in cancer aetiology and early-detection research (U01 clinical trial not allowed) funding opportunity. This supports research in cancer aetiology and early-detection biomarkers, using the biorepository resources of the NCI-sponsored PLCO screening trial. Projects may be in a wide range of cancer research, including biochemical and genetic analyses of cancer risk and discovery and validation of early detection biomarkers. Proposed research must make use of the PLCO biospecimens and should take advantage of the unique nature of the specimens.

Funding & Duration

Application budgets are not limited, but need to reflect actual needs of the project. The maximum project period is five years.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Access to Facilities, Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences and tagged . Bookmark the permalink.

Comments are closed.